| |
Zepatier Accepted by SMC - Scottish Medicines Consortium
|
| |
| |
Download the PDF here
January 2017 decisions news release
https://www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/January_2017_decisions_news_release
Elbasvir-grazoprevir (Zepatier) was accepted for the treatment of chronic Hepatitis C. Elbasvir – grazoprevir is a combination of two medicines that inhibit the replication of the Hepatitis C virus and offers the prospect of a cure for Hepatitis C infection.
"Eradicating hepatitis C is a key commitment for Scottish Government and new medicines for this condition will help achieve this aim."
--------------
A medicine giving the "prospect of a cure" for Hepatitis C is one of four accepted for routine use by NHS Scotland.
The Scottish Medicines Consortium (SMC) approved the use of Elbasvir-grazoprevir, known as Zepatier, on Monday, saying it is "a combination of two medicines that inhibit the replication of the Hepatitis C virus and offers the prospect of a cure for Hepatitis C infection".
-------------------------
Summary of Evidence SMC
elbasvir 50 mg, grazoprevir 100mg film-coated tablet (Zepatier®) SMC No. (1203/17)
Merck Sharp and Dohme Ltd
09 December 2016
The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and
Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission
elbasvir-grazoprevir (Zepatier®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).
In patients with genotype 1a, 1b or 4, elbasvir-grazoprevir significantly increased sustained virologic suppression compared with a regimen containing a non-structural protein 5B (NS5B) inhibitor, an interferon and ribavirin.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of elbasvir-grazoprevir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
|
|
| |
| |
|
|
|
